I’m sure the CEO over at IMU is making full use of her extensive scientific education, including her Master Of Fine Arts and Bachelor Of Science (Biology, Anthropology, Art History and Museum Studies) Of course, it provides a firm base for her subsequent 19 years experience in the drug industry.
Because KH only studied such non-scientific degrees in molecular biology, chemistry and biochemistry, before doing her Grad dip in IP Law and stuff. And then her 20+ years in the life sciences sector, of course, counts for zilch...
Not ‘sciencey’ enough, though.
Move on....again.
New drug "expected to hit the market within 2 years", page-60
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
-0.025(6.67%) |
Mkt cap ! $25.68M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.0¢ | 35.0¢ | $387.8K | 1.079M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 394907 | 35.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.5¢ | 15948 | 1 |
View Market Depth
| Last trade - 16.10pm 12/12/2024 (20 minute delay) ? |
| DXB (ASX) Chart |